Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caelyx + carboplatin versus paclitaxel + carboplatin in late-relapse epithelial ovarian cancer
NL-OMON30626Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and serous peritoneal carcinoma (PPSC) comparing Caelyx + carboplatin with Paclitaxel + carboplatin (2 arms). Primary endpoint: Progression-free survival. Started Jun 2007; status: active, not recruiting.
02
Drugs
pegylated liposomal doxorubicincarboplatinpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)serous peritoneal carcinoma (PPSC)
Beyond the preview
Go deeper on NL-OMON30626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30626.